New drug combo targets Hard-to-Treat skin cancer

NCT ID NCT05414500

Terminated Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests two drugs, mogamulizumab and brentuximab vedotin, given together to people with a rare type of skin lymphoma (CTCL or mycosis fungoides) that has not responded to prior treatment. The main goal is to see if the combination is safe and to find the best dose. Only 10 participants are enrolled, and the study is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mogamulizumab and brentuximab vedotin
What this could lead to: If it works, this could point toward a new treatment option for people with cutaneous T-cell lymphoma who have already tried other therapies.
What could go wrong: This is a very early, small Phase 1 trial (only 10 people) focused on safety, not yet on effectiveness. The study is currently suspended, so results may be delayed or never come.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T-CELL LYMPHOMA MYCOSIS FUNGOIDES

Contacts and locations

Locations

University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.